Reversibly Soluble Nicotinamide Cofactors

描述（由申请人提供）：辅因子回收是主要的 辅因子依赖性酶催化反应的障碍。的发展 容易回收的可逆可溶形式的烟酰胺辅因子是 本提案的重点。该思想包括辅因子修改， 可逆可溶性聚合物。因此，辅因子可以再次溶解 在起始原料的溶液或悬浮液中， 条件因此，这些辅因子获得了永久性的优点， 可溶性辅因子（在均相和非均相系统中均具有高活性） 和固定的辅因子（容易回收）。如今， 可溶性辅因子这一想法的潜力在 初步研究。该提案的第一阶段侧重于选择最佳方案 合成热响应和pH响应可逆可溶性辅因子的方法。 优化其合成，开发专有技术， 使用可逆可溶性辅因子制造手性药物将是 第二阶段的目标。也没有关于合成 可逆可溶性辅因子或其用于合成的用途。可逆可溶 辅因子和手性化合物将销售给制药公司。在 2000年，手性化合物的市场总额达到40亿美元。 拟议的商业应用： 可逆可溶性辅因子是独特的，因为它们结合了可溶性辅因子和固定化辅因子的联合收割机优点。没有这种类型的辅因子可商购获得。它们将在Polium Technologies内部使用，并出售给制药公司以制造手性中间体。手性中间体的市场每年约为40亿美元。仅生产一种药物的中间体的销售每年就能带来数百万美元的收入。

DESCRIPTION (provided by applicant): Cofactor recovery is one of the major hurdles of cofactor-dependent enzyme-catalyzed reactions. The development of easily recoverable reversibly soluble form of nicotinamide cofactors is the focus of this proposal. The idea consists of the cofactor modification with reversibly soluble polymers. Consequently, the cofactor can be dissolved again in a solution or suspension of the starting materials at the initial conditions. Therefore, these cofactors acquire the advantages of permanently soluble cofactors (high activity both in homogeneous and heterogeneous systems) and of immobilized cofactors (easy recovery). Today, there are no reversibly soluble cofactors on the market. Potential of the idea was demonstrated during preliminary studies. Phase I of the proposal focuses on the choice of the best method to synthesize thermo- and pH responsive reversibly soluble cofactors. Optimization of their synthesis, development of the proprietary technology to manufacture chiral pharmaceuticals using reversibly soluble cofactors will be the goals of Phase II. There are no patents either on the synthesis of reversibly soluble cofactors or their use for synthesis. Reversibly soluble cofactors and chiral compounds will be marketed to pharmaceutical companies. In 2000, total market for chiral compounds reached $4 billion. PROPOSED COMMERCIAL APPLICATIONS: Reversibly soluble cofactors are unique because they combine advantages of soluble and immobilized cofactors. There are no cofactors of this kind commercially available. They will be used internally at Polium Technologies and sold to pharmaceutical companies to manufacture chiral intermediates. Market for chiral intermediates is about $4 billion per year. Sales of intermediates for a production of just one drug can bring several million annually.